Method and device for detecting and quantifying glucose in body fluids

Claim 3

The method of claim 1 wherein said body fluid sample is chosen from the group consisting of a urine sample and a blood sample.

Claim 4

The method of claim 1 wherein at least one member of said specific binding pair is provided on a solid support for use in repeatedly contacting body fluid samples.

Claim 5

The method of claim 1 wherein said specific binding pair is provided on a support having a membrane positioned thereon in such a manner that it covers the specific binding pair, said membrane having a pore size which prevents passage of said binding pair from the support to the body fluid but permits passage of glucose between the body fluid and the support.

Claim 6

An in vivo method for determining glucose concentration in an individual, comprising the steps of: a) placing a sensor in communication with glucose present in the body fluids of the individual in such a way that once in place said sensor does not exit the skin of the individual, thereby permitting non-invasive monitoring of the glucose concentration in the body fluids of the individual, said sensor comprising a specific binding pair which comprises a first member which is a glucose-binding ligand labelled with a first light-absorbing material and a second member which is a glycoconjugate labelled with a second light-absorbing material, the excited state energy level of the first light-absorbing material overlapping with the excited state energy level of the second light-absorbing material, said ligand and said glycoconjugate being chosen such that over the range of physiological concentrations of glucose found in body fluids ranging from 0.05 mg/mL to 5.0 mg/mL they reversibly bind to each other such that glucose present in the individual's body fluid can displace said glycoconjugate and reversibly bind to said ligand; b) non-invasively monitoring the extent to which non-radiative fluorescence energy transfer occurs between the first light-absorbing material and the second light absorbing material in the presence of the glycoconjugate displaced by glucose and the ligand reversibly bound to glucose; and c) comparing the result of step (b) with the relationship between the extent of non-radiative energy transfer and glucose concentration in the individual's body fluids determined in a calibration step.

Claim 7

An in vivo method for determining glucose concentration in an individual, comprising the steps of: a) placing a sensor in communication with glucose present in the body fluids of the individual in such a way that once in place said sensor does not exit the skin of the individual, thereby permitting non-invasive monitoring of the glucose concentration in the body fluids of the individual, said sensor comprising a specific binding pair which comprises a first member which is a glucose-binding ligand labelled with a first light-absorbing material and a second member which is a glycoconjugate labelled with a second light-absorbing material, the excited state energy level of the first light-absorbing material overlapping with the excited state energy level of the second light-absorbing material, said ligand and said glycoconjugate being chosen such that over the range of physiological concentrations of glucose found in body fluids ranging from 0.05 mg/mL to 5.0 mg/mL they reversibly bind to each other such that glucose present in the individual's body fluid can displace said glycoconjugate and reversibly bind to said ligand; b) non-invasively monitoring the extent to which non-radiative fluorescence energy transfer occurs between the first light-absorbing material and the second light absorbing material in the presence of the glycoconjugate displaced by glucose and the ligand reversibly bound to glucose; and c) comparing the result of step (b) with the relationship between the extent of non-radiative energy transfer and glucose concentration in the individual's body fluids determined in a calibration step.

Claim 8

The method of claim 5 wherein said method measures the concentration of glucose in the individual's subcutaneous body fluid, intracutaneous body fluid, or blood.

Claim 9

The method of claim 5 wherein said ligand is a glucose-binding lectin.

Claim 10

The method of claim 5 wherein said ligand is Concanavalin A.

Claim 11

The method of claim 5 wherein the carbohydrate present in said glycoconjugate is capable of binding to glucose-binding ligands.

Claim 12

The method of claim 1 or claim 5 wherein said glycoconjugate is chosen from the group consisting of glycosylated serum albumin capable of binding to glucose-binding ligands and glycosylated bovine serum albumin capable of binding to glucose-binding ligands.

Claim 13

The method of claim 5 wherein said first and second light-absorbing materials are fluorophores.

Claim 14

The method of claim 11 wherein at least one of fluorophores is chosen from the group consisting of fluorescein and rhodamine.

Claim 15

The method of claim 5 wherein said ligand is labelled with a fluorophore which is the donor and said glycoconjugate is labelled with a fluorophore which is the acceptor in the non-radiative fluorescence resonance energy transfer process.

Claim 16

The method of claim 5 wherein said ligand is labelled with a fluorophore which is the acceptor and said glycoconjugate is labelled with a fluorophore which is the donor in the non-radiative fluorescence resonance energy transfer process.

Claim 17

The method of claim 5 wherein the non-radiative fluorescence resonance energy transfer is determined by measuring the ratio of the light emissions attributable to the first and second light absorbing molecules.

Claim 18

The method of claim 5 wherein the first member of the specific binding pair is rhodamine-labelled Concanavalin A, the second member of the specific binding pair is fluorescence-labelled glycosylated serum albumin capable of binding to glucose-binding ligands, and the non-radiative fluorescence resonance energy transfer is determined by measuring the ratio of the light emissions attributable to rhodamine and fluorescein.

Claim 19

The method of claim 5 wherein said sensor is placed on, in, or under the skin of the individual.

Claim 20

The method of claim 5 wherein said specific binding pair is placed in a microdialysis vessel and then subcutaneously implanted in the individual.

Claim 21

The method of claim 5 wherein said specific binding pair is encapsulated and then subcutaneously implanted in the individual.

Claim 22

The method of claim 5 wherein said specific binding pair is mixed with an oil into which glucose can pass and then injected subcutaneously in the individual.

Claim 23

The method of claim 5 wherein said specific binding pair is tatooed into the skin of the individual.

Claim 24

The method of claim 5 wherein the components of said specific binding pair are chemically modified to enable them to bind to the cells of the individual.

Claim 25

The method of claim 5 wherein said specific binding pair is bound to a solid support which is then implanted in the individual, said support retaining said specific binding pair at the desired location once implanted in the individual.

Claim 26

The method of claim 5 wherein said said specific binding pair is illuminated, and said energy transfer is monitored, through the skin of the individual.

Claim 27

The method of claim 5 wherein the non-radiative fluorescence resonance energy transfer is determined by assessing whether there is a decrease in donor lifetime, a quenching of donor fluorescence, an enhancement of acceptor fluorescence intensity or a depolarization of fluorescence relative to excitation, alone or in combination.

Claim 28

A sensor for non-invasively monitoring glucose concentration in an individual comprising a specific binding pair which comprises a first member which is a glucose-binding ligand labelled with a first light-absorbing material and a second member which is a glycoconjugate labelled with a second light-absorbing material, the excited state energy level of the first light-absorbing material overlapping with the excited state energy level of the second light-absorbing material, said ligand and said glycoconjugate being chosen such that they reversibly bind to each other over the physiological range of glucose concentrations found in the body fluid of the individual ranging from 0.05 mg/mL to 5.0 mg/mL to enable glucose present in the individual's body fluid to displace said glycoconjugate and reversibly bind to said ligand, the components of said sensor being configured such that once implanted in the individual said sensor does not exit the skin of the individual, thereby permitting non-invasive monitoring of the glucose concentration in the body fluids of the individual in the presence of the glycoconjugate displaced by glucose and the ligand reversibly bound to glucose.

Claim 29

A sensor for non-invasively monitoring glucose concentration in an individual comprising a specific binding pair which comprises a first member which is a glucose-binding ligand labelled with a first light-absorbing material and a second member which is a glycoconjugate labelled with a second light-absorbing material, the excited state energy level of the first light-absorbing material overlapping with the excited state energy level of the second light-absorbing material, said ligand and said glycoconjugate being chosen such that they reversibly bind to each other over the physiological range of glucose concentrations found in the body fluid of the individual ranging from 0.05 mg/mL to 5.0 mg/mL to enable glucose present in the individual's body fluid to displace said glycoconjugate and reversibly bind to said ligand, the components of said sensor being configured such that once implanted in the individual said sensor does not exit the skin of the individual, thereby permitting non-invasive monitoring of the glucose concentration in the body fluids of the individual in the presence of the glycoconjugate displaced by glucose and the ligand reversibly bound to glucose.

Claim 30

The sensor of claim 26 wherein said first member of said specific binding pair is a fluorescently-labelled lectin and said second member of said specific binding pair is a fluorescently-labelled blycoconjugate.

Claim 31

The sensor of claim 26 wherein said first member of said specific binding pair is rhodamine-labelled Concanavalin A and said second member of said specific binding pair is fluorescein-labelled glycosylated serum albumin capable of binding to glucose-binding ligands.